Clonality assurance and the rise of therapeutic monoclonal antibody development
Monoclonal antibodies – a recent history Over three decades ago, in 1986, the first monoclonal antibody (mAb) treatment was approved by the United States Food and Drug Administration (US FDA)[1].
Solentim to launch the ICON™ in 2021
Solentim is happy to announce that its new Cell Line Development platform, the ICON, will launch early 2021. For over a decade, Solentim has provided leading solutions to create, isolate
Is it time for a new standard for the culture of iPSCs?
For those delivering advanced therapy medicinal products, the question of assessing and managing cell population heterogeneity presents an ongoing challenge. Solentim and EverCell Bio addressed this topic at a recent
Solentim to present online at the 9th Cell Line Development & Engineering Asia digital conference
Solentim is happy to announce that it will be presenting at the 9th Cell Line Development & Engineering Asia conference, taking place 3-5 November 2020. This digitally delivered event brings together the
Solentim Cell Metric and VIPS selected by US Government Lab to support latest vaccine research
As part of the concerted fight against COVID-19, the Vaccine Research Center (VRC) at the National Institute for Allergy and Infectious Diseases at the U.S. National Institutes of Health has
Solentim to supply cell line development solutions for Samsung Biologics’ new R&D center in San Francisco
Bournemouth, UK, 7th October 2020 / Solentim is pleased to announce the adoption of its VIPS™ single cell seeding platform and Cell Metric® CLD into Samsung Biologics’ new research and development facility in San Francisco, CA. These